Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03377556
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:07.530550+00:00
Published At
2021-06-23T00:00:00+00:00
Record Updated At
2021-06-23
Results Posted At
2021-06-23
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["ATM Gene Mutation", "ATR Gene Mutation", "BARD1 Gene Mutation", "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "BRIP1 Gene Mutation", "CHEK1 Gene Mutation", "CHEK2 Gene Mutation", "FANCA Gene Mutation", "FANCC Gene Mutation", "FANCD2 Gene Mutation", "FANCF Gene Mutation", "FANCM Gene Mutation", "NBN Gene Mutation", "PALB2 Gene Mutation", "RAD51 Gene Mutation", "RAD51B Gene Mutation", "RAD54L Gene Mutation", "Recurrent Squamous Cell Lung Carcinoma", "RPA1 Gene Mutation", "Stage IV Squamous Cell Lung Carcinoma AJCC v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-06-23"
protocolSection.identificationModule.nctId
"NCT03377556"
protocolSection.identificationModule.officialTitle
"A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2021-06-23"

Study condition terms

  • ATM Gene Mutation (protocolSection.conditionsModule.conditions)
  • ATR Gene Mutation (protocolSection.conditionsModule.conditions)
  • BARD1 Gene Mutation (protocolSection.conditionsModule.conditions)
  • BRCA1 Gene Mutation (protocolSection.conditionsModule.conditions)
  • BRCA2 Gene Mutation (protocolSection.conditionsModule.conditions)
  • BRIP1 Gene Mutation (protocolSection.conditionsModule.conditions)
  • CHEK1 Gene Mutation (protocolSection.conditionsModule.conditions)
  • CHEK2 Gene Mutation (protocolSection.conditionsModule.conditions)
  • FANCA Gene Mutation (protocolSection.conditionsModule.conditions)
  • FANCC Gene Mutation (protocolSection.conditionsModule.conditions)
  • FANCD2 Gene Mutation (protocolSection.conditionsModule.conditions)
  • FANCF Gene Mutation (protocolSection.conditionsModule.conditions)
  • FANCM Gene Mutation (protocolSection.conditionsModule.conditions)
  • NBN Gene Mutation (protocolSection.conditionsModule.conditions)
  • PALB2 Gene Mutation (protocolSection.conditionsModule.conditions)
  • RAD51 Gene Mutation (protocolSection.conditionsModule.conditions)
  • RAD51B Gene Mutation (protocolSection.conditionsModule.conditions)
  • RAD54L Gene Mutation (protocolSection.conditionsModule.conditions)
  • Recurrent Squamous Cell Lung Carcinoma (protocolSection.conditionsModule.conditions)
  • RPA1 Gene Mutation (protocolSection.conditionsModule.conditions)
  • Stage IV Squamous Cell Lung Carcinoma AJCC v7 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.